Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

with three companies – Takeda, Celgene (currently under a merger agreement with Bristol-Myers Squibb) and AbbVie – reporting over 15% YoY growth. Takeda’s revenue increased by 18.5% to $18 ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company ... $2 billion through IPOs by September 3, a 24% year-over-year increase. However, two-thirds of these funds ...

While Sauerbronn is pleased with the progress Takeda is making in reducing its debts, helped by strong cash flows and a slew of asset sales, margin growth has been slower than he expected.

This is the third transaction in FY19 that furthers Takeda’s strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.

Takeda-backed Ascentage Pharma Group (AAPG) has filed to raise up to $100M through a U.S. initial public offering. The Chinese drug developer didn't specify terms in its SEC filing, but indicated ...